


# Mauritania

African Region




## I. Epidemiological profile

Population (UN)	2016	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	2,770,000	64	Plasmodium species: <i>P. falciparum</i> (100%), <i>P. vivax</i> (0%)
Low transmission (0-1 cases per 1000 population)	1,530,000	36	Major anopheles species: <i>An. gambiae</i> , <i>An. arabiensis</i> , <i>An. pharoensis</i>
Malaria-free (0 cases)	-	-	Reported confirmed cases (health facility): 29,156 Estimated cases: 313,000 [139,500–563,000]
Total	4,301,000	-	Confirmed cases at community level: - Reported deaths: 317 Estimated deaths: 1,200 [1,000–1,400]


## II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	1998	First-line treatment of unconfirmed malaria	AS+AQ	-					
	ITNs/ LLINs distributed to all age groups	Yes	-	First-line treatment of <i>P. falciparum</i>	AL; AS+AQ	-					
IRS	IRS is recommended	Yes	-	Treatment failure of <i>P. falciparum</i>	-	-					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	QN	-					
Larval control	Use of larval control recommended	No	2013	Treatment of <i>P. vivax</i>	-	-					
IPT	IPT used to prevent malaria during pregnancy	Yes	2008	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2011	Type of RDT used		-					
	Malaria diagnosis is free of charge in the public sector	Yes	2009								
Treatment	ACT is free of charge for all ages in public sector	Yes	2009	<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Is banned	-	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-	AS+AQ	2012-2012	1.8	1.8	1.8	28 days	2	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	2014	CQ	2012-2012	0	0	0	28 days	2	<i>P. vivax</i>
	G6PD test is a requirement before treatment with primaquine	Yes	2014	<b>Insecticide resistance tests (mosquito mortality, %)</b>							
	Directly observed treatment with primaquine is undertaken	No	-	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
System for monitoring adverse reactions to antimalarials exists	Yes	2009									
Surveillance	ACD for case investigation (reactive)	-	-								
	ACD of febrile cases at community level (pro-active)	-	-								
	Mass screening is undertaken	Yes	-								
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	Yes	-								
	Foci and case investigation undertaken	-	-								
Case reporting from private sector is mandatory	Yes	2014									



## III. Financing





## Government expenditure by intervention in 2016




## IV. Coverage



## V. Impact



## Confirmed malaria cases per 1000 and ABER



## Malaria admissions and deaths (per 100 000)

